Focus: Rhythm Pharmaceuticals is a publicly traded specialty pharma company focused on peptide therapeutics for neurology, anchored by IMCIVREE (setmelanotide) for rare genetic obesity. The company is at peak commercialization phase with 201-500 employees and strong R&D investment.
Profile data last refreshed 17h ago · AI intelligence enriched 1mo ago
Growing — net +11 jobs in 30d
24 jobs added vs 13 removed. Steady team buildout.
High-growth commercial play suitable for sales/marketing careers, but early-stage science fundamentals and cash-intensive model pose long-term sustainability risk.
FDA-approved MC4R agonist driving FY 2025 revenue growth; peak commercial phase with ~12-year patent runway.
Help build intelligence for Rhythm Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rhythm Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - Yahoo Finance UK
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Yahoo Finance UK
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - ad-hoc-news.de
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks ad-hoc-news.de
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs Stock Titan
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units Stock Titan
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases - Stock Titan
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases Stock Titan
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease - BioSpace
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo